In its April 2019 NEWSletter, the Patented Medicine Prices Review Board (PMPRB) announced that the Steering Committee on Guidelines Modernization would hold its final meeting on May 13, 2019, to discuss both a draft report of its deliberations and the Working Group’s final report (released March 6, 2019). Once the Steering Committee’s report has been finalized and the regulatory amendments have been published in Part II of the Canada Gazette (expected this spring), the PMPRB will release its draft Guidelines for public consultation.
Related Publications & Articles
-
Update on biosimilars in Canada – June 2025
This article provides an update on developments in the biosimilar space in Canada—regulatory, approvals, pending submissions, litigation, and market access.Read More -
CDA opens consultation on proposed list of drugs to inform development of national formulary
On June 19, 2025, Canada’s Drug Agency (CDA) opened a public consultation on a proposed process for preparing a list of essential prescription drugs and related products.Read More -
Finalized PMPRB Guidelines published
On June 30, 2025, the Patented Medicine Prices Review Board (PMPRB) published its new Guidelines for PMPRB Staff, which will come into force on January 1, 2026.Read More